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Summary
Objective: In 2015, the International League Against Epilepsy (ILAE) proposed a
new definition of status epilepticus (SE): 5 minutes of ongoing seizure activity to
diagnose convulsive SE (CSE, ie, bilateral tonic–clonic SE) and 10 minutes for
focal SE and absence SE, rather than the earlier criterion of 30 minutes. Based on
semiology, several types of SE with prominent motor phenomena at any time (in-
cluding CSE) were distinguished from those without (ie, nonconvulsive SE,
NCSE). We present the first population‐based incidence study applying the new
2015 ILAE definition and classification of SE and report the impact of the evolu-
tion of semiology and level of consciousness (LOC) on outcome.
Methods: We conducted a retrospective population‐based incidence study of all
adult patients with SE residing in the city of Salzburg between January 2011 and
December 2015. Patients with hypoxic encephalopathy were excluded. SE was
defined and classified according to the ILAE 2015.
Results: We identified 221 patients with a median age of 69 years (range 20‐99
years). The age‐ and sex‐adjusted incidence of a first episode of SE, NCSE, and
SE with prominent motor phenomena (including CSE) was 36.1 (95% confidence
interval [CI] 26.2‐48.5), 12.1 (95% CI 6.8‐20.0), and 24.0 (95% CI 16.0‐34.5;
including CSE 15.8 [95% CI 9.4‐24.8]) per 100 000 adults per year, respectively.
None of the patients whose SE ended with or consisted of only bilateral tonic–clo-
nic activity died. In all other clinical presentations, case fatality was lower in
awake patients (8.2%) compared with patients with impaired consciousness (33%).
Significance: This first population‐based study using the ILAE 2015 definition
and classification of SE found an increase of incidence of 10% compared to previ-
ous definitions. We also provide epidemiologic evidence that different patterns of
status evolution and LOCs have strong prognostic implications.
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1 | INTRODUCTION
Status epilepticus (SE) is a life‐threatening condition, with
substantial mortality and morbidity in survivors.1 SE was
defined traditionally as 30 minutes of ongoing epileptic
activity or seizures without recovery in‐between. In 2015, a
Task Force of the International League Against Epilepsy
(ILAE) proposed to define SE as bilateral tonic–clonic
activity lasting longer than 5 minutes, and absence SE and
focal SE as exceeding 10 minutes.2 The new ILAE classifi-
cation of SE 2015 distinguishes nonconvulsive SE (NCSE)
from SE with prominent motor phenomena. This allows
epidemiologic investigation of NCSE and its different sub-
types in population‐based studies. The changes of semiol-
ogy during one episode of SE, the level of consciousness
(LOC), and their impact on outcome have not yet been
investigated in a population‐based setting.
Previous studies on the epidemiology of SE found inci-
dence rates ranging from 3.5 to 41 per 100 000 per year in
North America,3–8 9.9 to 27.2 in Europe,9–14 1.3 to 5.2 in
Asia,15–17 and 10.8 in Africa.18 As a consequence of the
shorter diagnostic time with the ILAE 2015 definition, we
expected to identify more patients with SE. The ILAE pro-
posal also endorsed changes in categorization of etiology.
Therefore, the aim of this retrospective epidemiologic study
was to provide population‐based data on incidence, types,
and causes of SE according to the 2015 ILAE definition
and classification. In addition, we aimed to assess the
impact on outcome of the evolution of the clinical presen-
tation of SE and LOCs. This study was conducted accord-
ing to the STrengthening the Reporting of OBservational
studies in Epidemiology (STROBE) statement.19
The significance of this research is to obtain real‐world
population‐based data on the incidence of SE and its sub-
forms, in particular of NCSE, using the ILAE 2015 defini-
tion and classification. We also investigated the evolution
of semiology and the LOC and their impact on outcome
without any a priori assumptions or boundaries due to clas-
sification systems.
2 | METHODS
2.1 | Study design
We performed a retrospective population‐based incidence
study of all adult patients (age 18 years or older) with a
new diagnosis of a first episode of SE within the political
borders of the city of Salzburg, Austria, from January 1,
2011, to December 31, 2015. Patients were identified retro-
spectively by searching the hospital patient management
system for the terms “status epilepticus,” “convulsive sta-
tus,” “non‐convulsive status,” “focal status,” or “aphasic
status” in electroencephalography (EEG) reports or medical
reports for inpatients and outpatients. Cases were identified
at the Department of Neurology of Paracelsus Medical
University, Christian Doppler Medical Center, which pro-
vided the only 24/7 EEG and neurologic emergency service
in the city. All patients who presented at other hospitals in
the city of Salzburg with acute neurologic symptoms or
signs potentially qualifying for acute seizures and SE were
admitted to our neuroemergency unit by ambulance or were
seen acutely by our consultant neurologists in the respec-
tive hospitals. Medical and EEG reports of these consulta-
tions were included in this study. Patients residing in
nursing homes with seizures or status were also referred to
our department for treatment. Nurses were allowed to give
antiseizure medication only after prescription by the treat-
ing physician. This practice is limited to the younger
patient group (up to 18 years), which was not included in
our study. Therefore, we expected to have complete cover-
age of all patients with SE in that area. At least 2 neurolo-
gists were on duty, and both they and the EEG service
were available 24/7 (24/7 EEG service was established in
our institution in 1995). Patients with SE in the epilepsy
monitoring unit and those with hypoxic encephalopathy
Key Points
• Nonconvulsive status epilepticus (SE) had an
annual incidence of 12.1 per 100 000 adults, SE
with prominent motor phenomena 24.0 (includ-
ing 15.8 CSE)
• The detected incidence of SE increased due to
the availability of emergency electroencephalog-
raphy (EEG), clear diagnostic criteria, and an
increasing elderly population
• Evolution of semiology in status epilepticus
affects outcome
• Prominent motor phenomena predispose to good
outcome and nonconvulsive parts in an SE epi-
sode to bad outcome; the sequence matters
• Concerning outcome, distinguish SE patients
fully awake or awake with reduced cognition
from SE patients in somnolence, stupor, or coma
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and status‐like EEG patterns after cardiac arrest were
excluded. Pairs of 2 neurologists (ML and GG) who were
experienced in epileptology and board‐certified neurophysi-
ologists reviewed the patient charts independently and
extracted the data. Consensus was reached by discussion or
by third opinion (ET) in case of disagreement.
2.2 | Diagnostic criteria
SE was diagnosed if diagnostic time exceeded 5 minutes of
ongoing seizure activity for convulsive SE, or 10 minutes
for absence status or focal status with or without impaired
consciousness.2 For comparison, we also calculated the
proportion of patients who met the traditional diagnostic
time criterion of 30 minutes.
If one SE episode included bilateral tonic–clonic parts
at any time, the event was classified as “convulsive” SE
according to ILAE 2015 classification, which takes into
consideration the most overt semiology.2 SE with promi-
nent focal motor phenomena, tonic SE, hyperkinetic SE,
and myoclonic SE, which had been classified traditionally
in the groups of complex or simple partial SE, depending
on the integrity of consciousness, were grouped together
with CSE as “SE with prominent motor phenomena”
(ILAE 2015).2
Nonconvulsive SE (or NCSE) was defined clinically as
an enduring epileptic condition with reduced or altered
consciousness, behavioral or vegetative abnormalities, or
merely subjective symptoms like auras, but (by definition)
without prominent focal or generalized convulsive move-
ments at any time.20 We also investigated the evolution of
semiology within one episode of SE and its impact on case
fatality. Therefore, one SE episode may include more than
one type of semiology, for instance nonconvulsive, focal
motor, tonic, myoclonic, and convulsive parts in a semio-
logic sequence.
2.3 | Clinical context
We applied the Salzburg consensus EEG criteria for confir-
mation of NCSE,21 but also included patients with subtle
clinical phenomena such as minor jerks or conjugate gaze
deviation and a very high clinical and paraclinical suspi-
cion of NCSE based on history, clinical presentation, acute
magnetic resonance imaging (MRI), or ictal hexamethyl-
propyleneamine oxime–single‐photon emission computed
tomography (HMPAO‐SPECT) to prevent underascertain-
ment. Salzburg criteria for NCSE are not 100% sensitive.21
Furthermore, if a patient presented with subtle motor phe-
nomena (eg, periorally) after sustained bilateral tonic–clo-
nic activity, then NCSE after CSE was diagnosed on
clinical grounds and treatment was initiated immediately.
All other patients with NCSE on presentation had to have
EEG abnormalities, even if they did not strictly fulfill the
Salzburg criteria. However, patients were excluded if
NCSE could not be distinguished from a seizure with
Todd’s phenomena. EEG studies were performed only in
case of clinical suspicion, as continuous EEG had not yet
been established during the study period. Full access to
health care is free in Austria, due to mandatory government
health care insurance. Thus we do not expect any referral
bias in our series.
We defined etiology as either symptomatic (acute,
remote, progressive, and SE defined in electroclinical syn-
dromes) or unknown (ie, cryptogenic).2 Acute etiology
referred to the first week after onset of the brain insult.
Refractory SE (RSE) was defined when first‐line therapy
with benzodiazepines and one second‐line treatment with
antiepileptic drugs (AEDs) failed.22 In superrefractory SE
(SRSE), status continued or recurred despite the use of
anaesthetics for longer than 24 hours.22 Nonsurvivors were
patients who died in the hospital or who were transferred
to a hospice at discharge.
2.4 | Statistical analysis
We included only patients residing in the census area “City
of Salzburg” with the census code (“Zählsprengel”) 50101.
We used standardization to adjust for age and sex, based
on the 2016 population of Austria as reference population.
The Austrian government statistical bureau, “Statistik Aus-
tria,” provided demographic data, with information strati-
fied for sex and age groups of the populations of Salzburg
and Austria during the period from January 1, 2011, to Jan-
uary 1, 2016.23
First, the cumulative incidence was calculated for the
entire observation period of 5 years. Subsequently, that
value was divided by 5 to obtain the average annual inci-
dence expressed as incident cases per 100 000 adults per
year. Case fatalities were calculated as percentages of all
nonsurvivors in the group of patients with first SE in the
5‐year study period. For calculating age‐ and sex‐specific
SE incidence and case fatality rates, we considered the
population of Salzburg in the year 2011 as the population
at risk. To investigate the impact of changes in the popula-
tion over time, we also estimated SE incidence and case
fatality rates separately for each year from 2011 to 2015
using the demographic information provided by “Statistik
Austria” for the respective year. Subsequently, the age‐
and sex‐specific estimates for incidence rates were multi-
plied with the corresponding reference population weights
and finally summed up to obtain age‐ and sex‐adjusted
rates for the reference population of Austria in 2016.
Details of statistical calculations are presented in Data S1,
and a template for adjustment to populations other than
Austria can be found in Table S1.
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In addition, we calculated 95% confidence intervals
(95% CIs) for both the crude (ie, unadjusted) and the age‐
and sex‐adjusted incidence rates, using the Agresti‐Coull
and Dobson methods, respectively. Both methods are supe-
rior to classical approaches (eg, asymptotic normal confi-
dence intervals) in the case of small numbers of
events.24,25 All statistical analyses were carried out using R
version 3.4.1 (R Core Team 2017, https://www.R-project.
org/).
For comparison of our results, we performed age and
sex adjustment of data from previous studies to the refer-
ence population of Austria in 2016. We adjusted the data
from the study by Hesdorffer and colleagues in the United
States4 to the Austria population 2016.
The local ethics committee approved this retrospective
noninterventional epidemiologic study. According to Aus-
trian regulations, this study did not need written informed
consent from the patients, since it involved a retrospective
analysis of anonymized data, and was noninterventional.
3 | RESULTS
In the year 2011, the census area 50 101 “City of Salzburg”
comprised 121 727 adults. Based on our search algorithm,
we identified 297 patients with SE, 238 of whom were
diagnosed as a first episode; 59 episodes were recurrent sta-
tus. Seventeen patients (7.1% of 238) were excluded
because clinical or paraclinical information was insufficient
to distinguish SE from a seizure with postictal Todd’s phe-
nomenon; all of them were survivors. Thus, we included
221 patients with a median age of 69 years (range 20‐99)
who had first episodes of SE. Demographic data and etiol-
ogy of our patient population are shown in Table 1. We
excluded 16 patients with NCSE related to anoxia during
the study period. The EEG confirmation referring to Salz-
burg criteria for NCSE was available in 88.7% (102/115) of
nonconvulsive semiology as the only or last semiology
(Table 2). The crude, unadjusted, incidence of first episode
of SE was 36.3 per 100 000 adults per year (95% CI 27.0‐
48.8): 37.9 (95% CI 25.4‐56.3) in women and 34.5 (95% CI
21.8‐53.9) in men. Age and sex adjustment to the reference
population, Austria 2016, revealed an incidence of 36.1 per
100 000 adults per year (95% CI 26.2‐48.5): 37.0 (95% CI
23.8‐54.9) in women and 35.1 (95% CI 21.2‐54.6) in men.
Age‐ and sex‐adjusted incidence for CSE was 15.8
(95% CI 9.4‐24.8), which was included in 24.0 (95% CI
16.0‐34.5) “with prominent motor phenomena” (together
with focal motor, tonic, clonic, and myoclonic SE); the
incidence was 12.1 (95% CI 6.8‐20.0) for NCSE (ie, “with-
out prominent motor phenomena”). Women represented
77.6% of NCSE and 44.8% of SE with prominent motor
symptoms. Results for each of the 5 study years are shown
in Figure 1. The total number of NCSE cases increased
from 20 cases in the years 2011 and 2012, to 48 cases in
the years 2014 and 2015; the number of cases of status
with prominent motor symptoms increased by 13.0% over
the same period.
Patients age 60 years or older had a substantially
increased incidence compared with adult patients younger
than 60 years (Figure S1). We found an age‐ and sex‐
adjusted incidence rate in the elderly of 79.9 (95% CI 53.4‐
114.8): 89.6 (95% CI 54.0‐139.7) in elderly women and
67.6 (95% CI 32.3‐124.7) in elderly men. Patients younger
than 60 years of age had an incidence of 18.1 (95% CI
10.1‐30.1): 12.8 (95% CI: 4.4‐29.0) in women, and 23.4
(95% CI 10.9‐44.0) in men.
The overall case fatality was 16.3% (95% CI 12‐21.8):
21.8% (95% CI 15.4‐29.9) in women and 9.3% (95% CI
TABLE 1 Demographic data of all first nonhypoxic status
epilepticus episodes in adults
All episodes of first SE (women N, %) 221 (124, 56.0)
Age (y), median (IQR) 69 (28)
Onset in hospital, N (%) 58 (26.2)
History of epilepsy, N (%) 90 (40.7)
Witnessed onset, N (%) 101 (45.7)
Types of etiology, N (%)
Symptomatic 217 (98.2)
Acute 80 (36.2)
Remote 103 (46.6)
Progressive 31 (14.0)
SE defined in electroclinical syndromes 3 (1.4)
Cryptogenic (unknown) 4 (1.8)
Etiology, N (%)
Cerebrovascular 100 (45.2)
Trauma 37 (16.7)
Metabolic 25 (11.3)
Tumors 23 (10.4)
Toxic 8 (3.6)
Degenerative disorders 7 (3.2)
Infectious 4 (1.8)
Immune‐mediated 4 (1.8)
Others 15 (6.8)
RSE episodes, N (%)/case fatality, % 45 (20.4)/39.5
RSE treated with a second or more AED,
but no anesthetics
41 (18.6)/41.5
RSE treated with anesthetics 4 (1.8)/25.0
SRSE episodes, N (%)/case fatality, % 8 (3.6)/37.5
Types of etiology are classified according to ILAE 2015. IQR, interquartile
range; RSE, refractory status epilepticus; SE, status epilepticus; SRSE, super‐
refractory status epilepticus.
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4.8‐16.9) in men. In the elderly, case fatality was 22.5%
(95% CI 16.4‐29.9): women 27.8% (95% CI 19.9‐37.5) and
men 12.0% (95% CI 5.3‐24.2). In patients younger than
60 years, case fatality was 4.1% (95% CI: 0.92‐11.7): 0.0%
(95% CI 0.0‐14.8) in women and 6.4% (95% CI 1.6‐17.8)
in men. The relative distribution and case fatalities of
subgroups of SE according to ILAE 2015 are presented in
Table 3. Evolution of semiology during one episode of SE
was found in 68 patients (30.8%). The impact of the evolu-
tion of semiology and LOC on outcome is presented in
Table 4 and Figure 2. Case fatality rates for NCSE, non-
convulsive semiology at the end of the semiologic
sequence, nonconvulsive semiology at the beginning of the
sequence, and no nonconvulsive semiology at all (ie, only
prominent motor phenomena) were 27.6%, 25.6%, 10.0%,
and 3.5%, respectively.
The diagnostic time criterion of 5 minutes for convul-
sive SE and 10 minutes for focal SE and absences, com-
pared with a 30‐minute diagnostic time, led to a 10%
increase in the detection of first SE (20/201). Eighteen
patients of these had convulsive SE, and the other 2
patients had NCSE. Twelve patients had remote etiology:
six had acute symptomatic and 2 had cryptogenic etiology.
Fourteen patients had preexisting epilepsy. The beginning
of SE was observed in 14 patients. All 20 patients sur-
vived. Following 10‐300 minutes (median 180 minutes) of
SE, cessation of SE without treatment occurred in 2.3% (5/
221) of cases; all of those patients survived. During the 5‐
year study period, there were 59 episodes of recurrent SE,
that is, 21.1% of all SE (59/280), with a case fatality of
10.2%.
The population of Salzburg consisted of >95% Cau-
casian individuals. Age and sex adjustment of the data
from the Rochester study4 to the current reference popula-
tion, Austria 2016 (Table S1), revealed an incidence of
23.7 per 100 000 adults per year.
The incidence of RSE was 7.2 per 100 000 adults per
year (95% CI 3.3‐13.8), which included all SE episodes
refractory to one benzodiazepine and one AED, irrespective
of further treatment with other AEDs or anaesthetics
TABLE 2 Diagnostic EEG criteria for nonconvulsive status
epilepticus,21 and nonconvulsive phase at the end in a semiologic
sequence of one SE episode
Diagnostic investigation N
Diagnostic criteria for nonconvulsive SE in EEG:21 102
Epileptiform discharges >25 per 10 s epoch 10
Spatiotemporal evolution 34
Epileptic discharges <25 per 10 s 17
Rhythmic activity 13
Epileptic discharges <25 per 10 s AND rhythmic activity 4
Subtle clinical phenomena 26
Epileptic discharges <25 per 10 s 13
Rhythmic activity 3
Epileptic discharges <25 per 10 s AND rhythmic activity 1
No EEG performed, observation in clinical context 9
Fluctuation 55
Epileptic discharges <25 per 10 s 47
Rhythmic activity 5
Epileptic discharges <25 per 10 s AND rhythmic activity 3
Rhythmic activity without fluctuation 5
Clinical improvement 12
Positive ictal HMPAO‐SPECT 1
EEG, electroencephalography; HMPAO‐SPECT, hexamethylpropyleneamine
oxime–single‐photon emission computed tomography.
FIGURE 1 Incidence of first status
epilepticus (SE) episode per 100 000 adults
per year with relative contribution of
nonconvulsive SE (NCSE), and “SE with
prominent motor phenomena” (SE‐PM),
which included convulsive SE (CSE). Bars
indicate 95% confidence intervals
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(Table 1). SRSE occurred with an incidence of 1.2 (95%
CI 0.1‐5.1). RSE treated only with AEDs had 44% acute
etiology, 25% remote, and 31% progressive disease,
whereas proportions in RSE with anesthetics were 35%,
61%, and 4%, respectively.
Stays in the neurologic intensive care unit (NICU)
lasted a median of 1 day (range 0‐91; mean 3.7). Comor-
bidities are presented in Table S2. Table S3 provides an
overview of the various treatment forms. Table S4 presents
the data concordant to the STROBE statement.
4 | DISCUSSION
This study showed an average cumulative incidence of first
nonhypoxic SE of 36.1 per 100 000 adults per year with
the new ILAE 2015 definition and classification of SE.
NCSE had an annual incidence of 12.1, whereas this rate
was 24.0 for SE with prominent motor phenomena (includ-
ing 15.8 for CSE).
The incidence of SE is considerably higher than previ-
ously reported in most epidemiologic studies (range 1.3 to
27.2/100 000 per year), with the exception of 41 in Rich-
mond (USA), which included a high proportion of African
Americans.3–18 Reducing the diagnostic time from 30 to
5 minutes in CSE, or to 10 minutes in focal SE or absence
SE, increased the resulting incidence only moderately (by
10%). Initially, we attributed the high incidence of SE to
the substantial proportion (29.4%) of elderly, as the elderly
showed a substantial increase in incidence after the age of
50 years in this, and several other studies (Fig-
ure S1).3,4,6,7,10,12–14,17,18 We adjusted the incidence of
18.3 per 100 000 total population per year found in Roche-
ster by Hesdorffer et al4 between 1965 and 1984, which
included 23.2% elderly, to our reference population, Austria
2016, and revealed an age‐ and sex‐adjusted incidence of
23.7 per 100 000 adults per year. However, our results are
still around 1.5 times higher than the adjusted data from
Rochester, which were obtained by a records‐linkage sys-
tem of the Rochester Epidemiology Project with subsequent
maximal ascertainment.4 Our study also assumes an almost
complete ascertainment, as the study area was a small area
within a much larger catchment area, in which our clinic
served all hospitals by liaison, with 24/7 availability of
neurologists and EEG. We assume that the high incidence
is due to a high proportion (34.4%) of NCSE in our study.
This is more than 2.5 times higher than the 13% of “non‐
motor” SE in the last of the 4 decades in the Rochester
study.4 Similar to our investigation, a study in Ferrara,
Italy, included 24/7 EEG service, and therefore presumably
had the same chance of diagnosing NCSE, but the inci-
dence of NCSE was not calculated separately because the
ILAE 2015 classification was not available at the time.14 In
our study, the incidence of NCSE more than doubled from
2011/2012 to 2014/2015, which coincided with the Salz-
burg consensus EEG criteria for NCSE becoming available
TABLE 3 Classification of status epilepticus according to ILAE
2015
Classification of status epilepticus
First SE
N = 221
(100%)
Case fatality
N = 36
(16.3%)
(A) With prominent motor symptoms 145 (65.6) 15 (10.3)
A.1 CSE (synonym: bilateral
tonic–clonic SE)
94 (42.5) 8 (8.5)
A.1.a. Generalized convulsive 3 (1.4) 0
A.1.b. Focal onset evolving into
bilateral convulsive SE
88 (39.8) 8 (9.1)
A.1.c. Unknown whether focal
or generalized
3 (1.4) 0
A.2 Myoclonic SE (prominent
epileptic myoclonic jerks)
0 0
A.2.a. With coma 0 0
A.2.b. Without coma 0 0
A.3 Focal motor 51 (23.1) 7 (13.7)
A.3.a. Repeated focal motor
seizures (including Jacksonian)
38 (17.2) 7 (18.4)
A.3.b. Epilepsia partialis continua 6 (2.7) 0
A.3.c. Adversive status 0 0
A.3.d. Oculoclonic status 0 0
A.3.e. Ictal paresis (ie, focal
inhibitory SE)
1 (0.45) 0
A.4 Tonic status 6 (2.7) 0
A.5 Hyperkinetic SE 0 0
(B) Without prominent motor
symptoms (ie, NCSE)
76 (34.4) 21 (27.6)
B.1 NCSE with coma (including
so‐called subtle SE)
7 (3.2) 3 (42.9)
B.2 NCSE without coma 69 (31.2) 18 (26.1)
B.2.a. Generalized 0 0
B.2.a.a. Typical absence status 0 0
B.2.a.b. Atypical absence status 0 0
B.2.a.c. Myoclonic absence status 0 0
B.2.b. Focal 69 (31.2) 18 (26.1)
B.2.b.a. Without impairment
of consciousness
1 (0.45) 0
B.2.b.b. Aphasic status 10 (4.5) 1 (10.0)
B.2.b.c. With impaired consciousness 58 (26.2) 17 (29.3)
B.2.c. Unknown whether
focal or generalized
0 0
B.2.c.a. Autonomic SE 0 0
CSE, convulsive status epilepticus; NCSE, nonconvulsive status epilepticus;
SE, status epilepticus.
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in 2013. Increasing awareness and a learning curve might
also be responsible for the increase in incidence over time.
The current study, and the studies performed in Bologna
and Lugo di Romagna (both Italy), are the only ones that
reported a female preponderance of SE.12,13 In Salzburg,
we found an especially high proportion of women (73%) in
our patients with NCSE. We have no clear explanation for
this, but speculate that an urban setting, as opposed to rural
services, facilitates women’s access to the health care sys-
tem, which may influence case ascertainment.
The age‐ and sex‐adjusted incidences of RSE of 7.2 per
100 000 adults per year (19.5% of all first SE episodes) and
of SRSE of 1.2 (3.6%) were moderately higher than in a
recently published Finnish population (RSE 2.7 and SRSE
0.75, combined 3.4/100 000).26 Our case fatalities of RSE
(39.5%, Table 1) and SRSE (37.5%) were influenced by the
small number of events, but were substantially higher than in
the Finnish study (7.4% in hospital),26 and in the global audit
for RSE (22.0%),27 but of the same order of magnitude as in a
large US study (31.8%).28 Overall case fatality was 16.3% in
this study, whereas in other studies it ranged from 5% in Fer-
rara to 39% (30‐day) in Bologna, both in Northern Italy.12,14
Our investigations revealed that poor outcome is not
correlated with prominent motor phenomena, but with the
TABLE 4 Outcome of patients with respect to the evolution of semiology and level of consciousness
Level of consciousness N
Case fatality,
% (95% CI)
Age, median
(range)
Etiology,
acute, N (%)
Etiology,
progressive, N (%)
(A) Convulsive semiology at the
end of SE, or as the
only semiology
NA 57 0.0 (0.0‐7.6) 63 (20‐91) 14 (24.5) 6 (10.5)
(B) Convulsive semiology at the
beginning of SE; focal
motor‐, tonic‐, myoclonic‐, and
nonconvulsive semiology
in a semiologic sequence; focal
motor SE, tonic SE,
myoclonic SE
Fully awake and awake with
reduced cognition
36 2.8 (0.0‐15.4)* 62 (25‐87) 6 (16.7) 5 (13.9)
Somnolence, stupor, coma 52 26.9 (16.7‐40.4)* 69 (23‐97) 23 (44.2) 6 (11.5)
(C) Nonconvulsive SE Fully awake, and awake with
reduced cognition
37 13.5 (5.4‐28.5) 71 (20‐94) 11 (29.7) 10 (27.0)
Somnolence, stupor, coma 39 41.0 (27.1‐56.6) 78 (25‐99) 25 (64.1) 5 (12.8)
(B and C) Fully awake, and awake with
reduced cognition
73 8.2 (3.5‐17.1)* 67 (20‐94) 17 (23.3) 15 (20.6)
Somnolence, stupor, coma 91 33 (24.1‐43.2)* 72 (23‐99) 48 (52.8) 11 (12.1)
NA, not applicable; SE, status epilepticus.
*Confidence intervals do not overlap.
FIGURE 2 Systematic investigation of outcome in relation to semiologic sequence and level of consciousness. Arrows allow reader to
follow particular semiologies with different levels of consciousness. Green shades denote nonconvulsive forms, orange and red shades denote
prominent motor forms, and blue shades denote various levels of consciousness
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occurrence of nonconvulsive phases in the semiologic
sequence. NCSE had a case fatality of 27.6%; this rate was
25.6% for SE with nonconvulsive semiology at the end of
the semiologic sequence, 10% for SE with nonconvulsive
semiology at the beginning of the sequence, and 3.5% for
only prominent motor phenomena. Therefore, it seems cru-
cial to search for nonconvulsive phases in the semiologic
sequence to estimate the risk for bad outcome, or, alterna-
tively, to search for prominent motor phenomena for good
outcome. The semiology that comes later determines the
outcome. Case fatality was zero when semiologic sequence
ended with or consisted of only bilateral tonic–clonic activ-
ity. Bilateral tonic–clonic activity might get noticed quickly
by bystanders and might reflect the early full cerebral
capacity of seizing without metabolic or electric exhaus-
tion.5,29 Indeed, our results challenge the historical view
that bilateral tonic–clonic activity at any time during a SE
episode should be classified as “convulsive” SE, irrespec-
tive of the position in the semiologic chain, the length of
time, and the other semiologies during SE. Other large
studies did not address this issue and failed to identify an
influence of semiology on outcome.30 The semiology hier-
archy should be reassessed and analyzed in future large
studies, to provide precise semiology and associated out-
come data.
With regard to LOCs, case fatality was 2.8% in patients
fully awake or awake with reduced cognition in the case of
SE with prominent motor phenomena, except CSE (LOC is
not meaningful in CSE). However, case fatality was 26.9%
if patients were somnolent, stuporous, or comatose
(Table 4). Accordingly, in the NCSE group, we found sim-
ilar case fatalities for fully awake (0.0%) and awake with
reduced cognition (13.9%), in contrast with somnolence
(36.8%), stupor (46.2%), and coma (42.9%) (Figure 2). We
suggest that future studies should investigate the semiologic
sequence with special emphasis on the identification of
nonconvulsive phases, and determine the levels of con-
sciousness (fully awake, awake with reduced cognition,
somnolent, stuporous, or comatose).
This study has several limitations. First, the retrospective
study design predisposed to underascertainment of sponta-
neously stopping episodes, and of those NCSE episodes that
were treated successfully before EEG service arrived. How-
ever, only EEG could differentiate between SE and a sei-
zure with Todd’s phenomenon in cases of otherwise
missing clinical features, such as minor jerking or forced
contralateral gaze deviation. Spontaneous cessation occurred
in around 20% of cases in a placebo‐controlled trial,31 but
only in 2.3% of cases in our study. We observed sponta-
neous cessation of SE up to 300 minutes after focal motor
SE without LOC. Therefore, prospective studies should
include spontaneously stopping SE at any time. We did not
review patients with epilepsy without a diagnosis of SE for
events meeting SE criteria. Such events may have been
coded as epilepsy as opposed to SE, in particular with
absence status. Second, one might argue that the retrospec-
tive design may result in inappropriate data acquisition rely-
ing on medical records. However, we have developed a
data acquisition sheet,32 which is standard operating proce-
dure in our department. This SE documentation sheet
accompanies the patient from our neuroemergency unit to
the EEG lab, normal ward, and neurologic intensive care
unit, ensuring the highest level of data reliability.32
Third, clinicians were free to decide in cases of SE
refractory to one benzodiazepine and one AED whether to
proceed with anesthetics or other AEDs. Case fatality was
41.0% in the group of RSE with further AED use, and
25.0% in RSE with anesthetics. We found no differences in
the pattern of comorbidities between those groups; how-
ever, there was a tendency of a higher proportion of acute
or progressive disease with nonsurvivors compared with a
higher rate of remote etiologies with survivors. Physicians
might have been reluctant to use anesthetics in patients
with progressive disease (eg, tumor), or acute diseases (eg,
severe stroke), who are already compromised and have an
increased chance of death. This may have confounded the
outcome data in our study. The use of intravenously
applied anesthetics was identified as an independent risk
factor in a recent 2‐center study.33 However, numbers in
our study were too small to draw firm conclusions.
Fourth, patients with other major medical problems who
were too ill to be transferred to their hospital could have
been missed. Therefore we assume a slight underestimation
of SE. However, we believe to have achieved the maxi-
mally possible coverage of SE.
Age strata of 5 years for study population and popula-
tion of Salzburg are provided to perform age and sex
adjustment of our data to any population (Table S1). This
allows calculation of health care impact in populations with
different population pyramids or in future populations esti-
mated by census bureaus.
In summary, this first population‐based study applying
the new ILAE (2015) diagnostic and classification criteria
for SE in a small urban area over 5 years, with a very low
probability of underascertainment, yielded an incidence of
SE almost 1.5 times higher than previously reported. This
finding is likely attributable to a high proportion of elderly
and a high rate of NCSE in this study. The present study
provides the first systematic epidemiologic evidence that
the evolution of semiology has an impact on clinical out-
come. Larger prospective multicenter studies are needed to
allow an even deeper understanding of outcome‐relevant
parameters. The current ILAE classification provides a
good starting point to address this issue.
We highlight the practical advantage of the ILAE 2015
definition and classification, which improves analysis of
8 | LEITINGER ET AL.
NCSE, and the need for meticulous assessment of the evo-
lution of semiology and LOCs to learn more about clinico-
pathologic correlations, which will improve outcome
prediction.
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